NCT04335682 - Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide | Biotech Hunter

Enrollment

111

Participants

Timeline

Start Date

August 17, 2021

Primary Completion Date

October 1, 2025

Study Completion Date

August 31, 2026

Conditions

Metastatic Prostate CancerProstate Cancer MetastaticProstate CancerCastrate Resistant Prostate CancerHormone Sensitive Prostate CancerNon-metastatic Prostate Cancer

Interventions

DRUG

Darolutamide

Patients randomized to darolutamide.

DRUG

Enzalutamide

Patients randomized to enzalutamide.

Trial Locations (8)

53226

Froedtert and the Medical College of Wisconsin, Milwaukee

55455

University of Minnesota, Minneapolis

60611

Northwestern University Feinberg School of Medicine, Chicago

60637

University of Chicago, Chicago

66205

University of Kansas Cancer Center, Fairway

73104

University of Oklahoma, Oklahoma City

94115

University of California - San Francisco at Mount Zion, San Francisco

02115

Dana Farber Cancer Institute, Boston